Premium
Transrectal ultrasound microbubble contrast angiography of the prostate
Author(s) -
Ragde Haakon,
Kenny Gerald M.,
Murphy Gerald P.,
Landin Kent
Publication year - 1997
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/(sici)1097-0045(19970901)32:4<279::aid-pros8>3.0.co;2-e
Subject(s) - medicine , prostate cancer , prostate , urology , ultrasound , prostatitis , biopsy , prostate specific antigen , radiology , rectal examination , prostate biopsy , cancer
BACKGROUND Prostate cancer, suspected by serum prostate‐specific antigen (PSA) elevation and/or digital abnormalities, is not always evident on gray‐scale or color Doppler transrectal ultrasound (TRUS). EchoGen® (Sonus Pharmaceuticals, Inc., Bothell, WA), a blood vessel image enhancer able to visualize smaller, low‐flow vessels and thus possibly the microvascular angiogenesis often associated with cancer, was employed to see if it would improve prostate cancer detection, particularly in patients with a rising serum PSA and prior negative biopsies. METHODS Color Doppler TRUS was performed before and after intravenous injection of 0.05 ml/kg of EchoGen®. Random and/or specifically directed sextant TRUS biopsies were performed. RESULTS Fifteen patients with serum PSA elevations were included in the study. Fourteen had a negative prior biopsy (1–3 ×). Prostate cancer was detected in 5 patients. Microvascular patterns were judged abnormal in 8 patients, 2 of which proved malignant, 2 of which were benign, and 1 of which was diagnosed with prostatitis. False‐negative results were observed in 3 patients, whose positive biopsy sites were from the prostate apex. CONCLUSIONS Following EchoGen® administration, prostate blood vessel image enhancement was noted in all patients, and there were no adverse reactions during or after EchoGen® administration with the dose employed. Prostate 32:279–283, 1997. © 1997 Wiley‐Liss, Inc.